Leading NightWare in its next phase of growth and expansion.

NightWare is an FDA cleared novel digital therapeutic for the treatment of disruptive nightmares associated with PTSD or other traumatic events. I lead the commercialization activities such as launch planning and strategy, sales and marketing, sales operations, social media, customer insights, and distributor arrangements and performance.Led overall company commercial strategyCreated brand, marketing, sales (direct and partner), pricing, and distribution strategy of the NightWare deviceEstablished the broad infrastructure for the execution of strategyGrew product from $0.00 to $5M trend annually

In collaboration with founders and VC, I help build healthcare companies that launch game changing products to improve the lives of others. I use proven frameworks to install an effective commercial and business infrastructure for early stage or launch success.

Strategy development for the VITAL program, a startup business of Highmark Health that significantly improves care, economics, and experience. • Drove revenue increase from $175k to $1.1m within one yearLed strategy development in the enterprise strategy and marketing strategy group• Led workstreams activities and staff of 5 for the advancement of enterprise strategic partnerships and innovation in the Strategy and Transformation Office.• Led a team of 9 strategists to grow the commercial health insurance business, drive uptake of pharmacy benefits, and drive adoption of innovative clinical care models with providers and members/patients.

Grew sales through development of commercial strategies [i.e. marketing, sales, comms, digital, ops, clinical, lifecycle] for a portfolio of pharma brands (~$1B in Sales) for Mylan North America's Specialty Business Unit (BU). • Led transformation of EpiPen business during launch of Authorized Generic after significant public relations issues. • Led development of enterprise commercial launch strategy of NCE (new chemical entity) as Chair of Joint Commercial Committee between Mylan and co-promote partner.• Redefined portfolio brand strategy and execution for in-market and pre-launch products to operate as a portfolio rather than individual brands.• Grew the revenue of 3 products and optimized the P&L 3 different products at the end of their life cycle to maximize portfolio profitability.• Built a high performing team of 7 marketers (3 new hires). Improved development, productivity, and satisfaction via new organizational structure.• Added significant use of low cost, high frequency digital and social media marketing approach for product portfolio.• Defined the customer response activities for Class 1 recall and warning letter related to epinepherine autoinjector.Sr Director, Specialty Brands• Drove revenue increases for 3 brands and launch planning a pre-launch product.Transformed a branded injectable anesthesia drug enterprise strategy and promotional plan. Exceeded both top line revenue (+62% over 3 years) and improved P&L of 19-year-old brand. Awarded Trailblazer Brand Champion Award by PM360.• Grew key respiratory brand in units and revenue after 5 years of decline through new commercial strategy and execution.• Defended patent as designated representative during depositions against third party who was challenging the molecule patent.• Defined business development and line extension opportunities for respiratory line that were designed to provide competitive defenses. Recommendations abandoned due to organization financial constraints.

Founded medical device distributorMedical device distributorship provided hospital systems and healthcare practitioners in Western PA innovative medical products. • Developed and executed plan resulting in product growth vs prior representation. Grew sales of keystone medical device 700%. • Employed, directed, and coached 2 sales people under 1099 arrangement. • Developed portfolio of 5 complementary products for individual portfolio.

• Grew portfolio sales through launch of newly acquired brands and redefining strategies for existing brands. Managed 5 brands, 4 marketers, and 1 inside sales representative. • Evaluated all licensing and acquisition opportunities related to product portfolio. Drove licensing agreement based on portfolio fit, revenue potential, and business synergies. • Grew brand trend by 15% for newly acquired bone hemostasis product through integration into Baxter portfolio. Maximized uptake within under-penetrated specialties while ensuring high-value portfolio brands were not cannibalized.• Led commercial integration of $275MM acquisition, a bone graft substitute into portfolio. Grew brand sales trend by 25% after assuming responsibility for brands. Led 2 marketers in rebranding products under Baxter umbrella. • Led transition of bone graft brand from distributor (1099) sales model to direct sales model. • Re-branded and re-messaged bone graft product line. Brand equity and recognition increased over 50%.• Grew surgical sealant brand from $27MM to $32MM during period of compliance shift to eliminate off-label use. Created sustainable and growing brand through rebranding of product. • Developed and implemented brand initiatives which drove on-label use from 35% to 65% of sales.• Grew topical hemostasis brand from $61MM to $111MM into the market leader during tenure.• 2008 BioSurgery President’s Club Winner, Global Marketing Innovation Award Winner, Global Brand Plan Runner-Up.

B2B sales role securing commercial and clinical multi-year contracts for the manufacture of injectable technologies for large and small pharma.